Showing 1-10 of 132 results for "".
- Jashin J. Wu, MD, FAADhttps://practicaldermatology.com/profiles/jashin-j-wu-md-faad/jJq5gl/
Updates on Psoriasis Biologics
https://practicaldermatology.com/programs/practical-dermatology/updates-on-psoriasis-biologics/35894/Jashin J. Wu, MD, discusses biologics for psoriasis, including a meta-analyses of best biologics for different types of the condition, at Music City SCALE 2025.Psoriasis Update: Understanding the Latest Psoriasis Guidelines
https://practicaldermatology.com/topics/psoriasis/psoriasis-update-understanding-the-latest-psoriasis-guidelines/19777/In a major reversal, the latest psoriasis guidelines recommend against yearly tuberculosis testing for psoriasis patients on biologics who are at low or no risk for TB, says Jashin J. Wu, MD. He also sheds light on studies comparing the 11 biologics that are currently approved for the treatment of pHS Tips and Lizards
https://practicaldermatology.com/programs/practical-dermatology/hs-tips-and-lizards/35858/The latest news and updates, plus a psoriasis update from Jashin J. Wu, MD, FAAD, at Music City SCALE, and Jennifer L. Hsiao, MD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss treating hidradenitis suppurativa and play a game of "Two Truths and a Lie."Introducing SDDS
https://practicaldermatology.com/topics/practice-management/introducing-sdds/19718/Jashin J. Wu, MD, Founder and Course Director, San Diego Dermatology Symposium, introduces a new meeting with topics in acne, psoriasis, pediatric dermatology, cutaneous oncology, and more. UPDATE: The inaugural 2020 San Diego Dermatology Symposium will be held September 11-13, 2020 at the InterConCOVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditi- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
What You Missed at San Diego Dermatology Symposium
https://practicaldermatology.com/topics/psoriasis/what-you-missed-at-san-diego-dermatology-symposium/19884/Jashin Wu, MD, founder of San Diego Dermatology Symposium, gives an overview of the 2020 meeting, which went virtual.Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Psoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.
- Prev
- Next